BiomX
BiomX is dedicated to advancing medicine through the development of customized phage therapies aimed at eradicating harmful bacteria associated with chronic diseases such as cystic fibrosis and diabetic foot osteomyelitis. The company focuses on discovering and validating proprietary bacterial targets and tailoring phage compositions to effectively combat these targets. BiomX is also engaged in collaborations to enhance its biomarker discovery capabilities and expand its therapeutic offerings.
BiomX
708 Quince Orchard Rd, Suite 205, Gaithersburg, MD 20878, USA
What We Do
A phage therapy targeting Pseudomonas aeruginosa in cystic fibrosis patients, currently in Phase II trials. Positive topline results from a Phase 1b/2a trial were announced in November 2023.
A phage therapy for diabetic foot osteomyelitis, currently in Phase II trials. Topline results are expected in Q1/2025.
BX005
An atopic dermatitis product candidate, currently in development with a right of first offer to license in Japan granted to Maruho Co. Ltd.
Regenerative Medicine
Digital Health Technologies
Key People
Funded Projects
BiomX Achieves Positive Phase 2 Results for BX211 in Treating Diabetic Foot Osteomyelitis
BiomX has reported positive Phase 2 results for BX211, its personalized phage therapy for Diabetic Foot Osteomyelitis (DFO). The treatment significantly improved ulcer healing, showing promise for reducing amputation risk. Supported by NMRC and MTEC, BX211 may offer new hope for both military and civilian patients.
News & Updates
BiomX has released its financial results for the third quarter of 2024, along with updates on its business and programs.
BiomX will host a conference call to discuss its third quarter 2024 financial results.